Controlled substances became a little less controlled during the pandemic. That benefited both patients (for their health) and telehealth startups (to make money). Some potentially addictive medications — like buprenorphine and Adderall — are now far more available online to patients because of regulatory changes. Given the scarcity of qualified doctors to treat some of the behavioral health conditions associated with these drugs, like opioid use disorder or attention-deficit/hyperactivity disorder, doctors’ new ability to prescribe online or, in some cases, by telephone is a huge change. But easier access to the drugs has both upsides and downsides, since they’re often dispens
Hence then, the article about behavioral telehealth loses momentum without a regulatory boost was published today ( ) and is available onKHN ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Behavioral Telehealth Loses Momentum Without a Regulatory Boost )